| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
119,920,000 |
| Market
Cap: |
2.21(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$14.96 - $32.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. Co.'s clinical-stage programs are: leucine-rich repeat kinase 2 inhibitor program to address Parkinson's disease; enzyme transport vehicle :IDS program, its lead brain-penetrant enzyme replacement therapy, enabled by its enzyme transport vehicle, which is designed to restore iduronate 2-sulfatase, and reduce glycosaminoglycans, both peripherally and in the brain, in patients with mucopolysaccharidosis II; and eukaryotic initiation factor 2 B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
97,506 |
194,997 |
252,199 |
526,275 |
| Total Sell Value |
$1,994,341 |
$3,816,456 |
$5,294,638 |
$13,483,252 |
| Total People Sold |
2 |
5 |
5 |
6 |
| Total Sell Transactions |
4 |
19 |
38 |
76 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ho Carole |
Chief Medical Officer |
• – – |
2019-04-03 |
4 |
AS |
$26.27 |
$154,319 |
D/D |
(5,862) |
0 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2019-04-03 |
4 |
OE |
$5.28 |
$30,951 |
D/D |
5,862 |
5,862 |
|
- |
|
| Watts Ryan J. |
President and CEO |
• • – |
2019-04-03 |
4 |
AS |
$26.28 |
$161,630 |
I/I |
(6,141) |
2,597,638 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2019-04-02 |
4/A |
AS |
$24.51 |
$155,194 |
D/D |
(6,242) |
0 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2019-04-02 |
4/A |
OE |
$5.28 |
$32,958 |
D/D |
6,242 |
6,242 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2019-04-02 |
4 |
AS |
$25.29 |
$238,864 |
I/I |
(9,445) |
132,670 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2019-04-02 |
4 |
AS |
$24.51 |
$152,503 |
D/D |
(6,135) |
0 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2019-04-02 |
4 |
OE |
$5.28 |
$32,393 |
D/D |
6,135 |
6,135 |
|
- |
|
| Watts Ryan J. |
President and CEO |
• • – |
2019-04-02 |
4 |
AS |
$24.52 |
$152,514 |
I/I |
(6,142) |
2,603,779 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2019-04-01 |
4 |
AS |
$23.91 |
$138,080 |
D/D |
(5,775) |
0 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2019-04-01 |
4 |
OE |
$5.28 |
$30,492 |
D/D |
5,775 |
5,775 |
|
- |
|
| Watts Ryan J. |
President and CEO |
• • – |
2019-04-01 |
4 |
AS |
$23.91 |
$144,656 |
I/I |
(6,050) |
2,609,921 |
|
- |
|
| Bratton Capital Inc. |
10% Owner |
– – • |
2019-03-25 |
4 |
D |
$0.00 |
$0 |
I/I |
(158,764) |
953,035 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2019-03-14 |
4 |
AS |
$25.01 |
$12,505 |
D/D |
(500) |
0 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2019-03-14 |
4 |
OE |
$5.28 |
$2,640 |
D/D |
500 |
500 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2019-03-14 |
4 |
AS |
$25.01 |
$12,505 |
I/I |
(500) |
142,115 |
|
- |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2019-03-13 |
4 |
AS |
$23.60 |
$60,387 |
I/I |
(2,512) |
655,089 |
|
- |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2019-03-12 |
4 |
AS |
$22.40 |
$56,291 |
I/I |
(2,513) |
657,601 |
|
- |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2019-03-11 |
4 |
AS |
$21.20 |
$52,635 |
I/I |
(2,475) |
660,114 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2019-03-05 |
4 |
AS |
$21.96 |
$128,730 |
D/D |
(5,862) |
0 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2019-03-05 |
4 |
OE |
$5.28 |
$30,951 |
D/D |
5,862 |
5,862 |
|
- |
|
| Watts Ryan J. |
President and CEO |
• • – |
2019-03-05 |
4 |
AS |
$21.97 |
$134,918 |
I/I |
(6,141) |
2,615,971 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2019-03-04 |
4 |
AS |
$21.87 |
$129,776 |
D/D |
(5,863) |
0 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2019-03-04 |
4 |
OE |
$5.28 |
$30,957 |
D/D |
5,863 |
5,863 |
|
- |
|
| Watts Ryan J. |
President and CEO |
• • – |
2019-03-04 |
4 |
AS |
$21.87 |
$135,958 |
I/I |
(6,142) |
2,622,112 |
|
- |
|
417 Records found
|
|
Page 14 of 17 |
|
|
0.42 (2.33%) 
